Search Results
Lead Left Bookrunner for Sound Point Meridian Capital, Inc.
Oppenheimer & Co. Inc. acted as Lead Left Bookrunner for Sound Point Meridian Capital, Inc. (NYSE: SPMC) on its $50.0 Million Offering of 8.00% Preferred Shares due 2029
Lead Bookrunner on Perspective Therapeutics' Confidentially Marketed Public Offering
Oppenheimer & Co. Inc. acted as Lead Bookrunner on Perspective Therapeutics’ $69MM Confidentially Marketed Public Offering
Lead Bookrunner on INOVIO Pharmaceuticals' Registered Direct Offering
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $50MM Private Placement Financing
Lead Bookrunner on INOVIO Pharmaceuticals' Public Offering of Common Stock
Oppenheimer & Co. Inc. acted as Lead Bookrunner on INOVIO Pharmaceuticals' $30.0MM Confidentially Marketed Public Offering of Common Stock
Lead Bookrunner and Structuring Agent on Sound Point Meridian Capital, Inc.'s Initial Public Offering
Oppenheimer & Co. Inc. acted as Lead Bookrunner and Structuring Agent on Sound Point Meridian Capital, Inc’s Initial Public Offering
Joint Bookrunning Manager on Soleno Therapeutics
Oppenheimer &. Co. Inc. acted as Joint Bookrunning Manager on Soleno Therapeutics’ $158,700,000 confidentially marketed public offering of common stock
Joint Bookrunner to Murano Global Investments PLC Senior Secured Notes Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner to Murano Global Investments PLC on its $300 million 144A/Reg S Green Senior Secured Notes Offering
Joint Bookrunner & Sole Ratings Advisor to Trans-Oil Group on its New US$550m Senior Secured Eurobond
Oppenheimer’s European Capital Markets Group is pleased to announce it acted as Joint Global Coordinator and Joint Bookrunner & Sole Ratings Advisor to Trans-Oil Group on its new US$550m 11.125% 5NC2 high yield bond offering
Joint Bookrunner on Voyager Therapeutics Confidentially Marketed Public Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Voyager Therapeutics’ $100MM Confidentially Marketed Public Offering
Joint Bookrunner on Trevi Therapeutics' Underwritten Registered Direct Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Trevi Therapeutics' $50.0MM Underwritten Registered Direct Offering